Akero Therapeutics Inc (AKRO NASDAQ) stock market data APIs
$37.761
-0.42(-1.1%)
as of April 21, 2025
Akero Therapeutics Inc Financial Data Overview
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Prev. Close
37.761
Open
37.3434
High
39.6456
Low
37.3434
52 wk Range
17.86-58.4
Market Cap
2 999 M
Shares Outstanding
79 620 K
EPS
-0.99
Beta
-0.18
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Akero Therapeutics Inc data using free add-ons & libraries
Get Akero Therapeutics Inc Fundamental Data
Akero Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -285 404 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-26
- EPS/Forecast: -1.1228
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Akero Therapeutics Inc News
New
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Akero Therapeutics, Inc. ("Akero")...
Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf
PHILADELPHIA, March 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ: AKRO): Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary...
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Agilon Health (AGL) is a stock that can certainly grab the atten...
Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025
We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025.In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
